Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1923MR)

This product GTTS-WQ1923MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species synthetic construct
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ1923MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ840MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ12177MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ15127MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ13958MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ4439MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ1387MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ9743MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JR-141
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW